EX-99.9 7 fs42022a3ex99-9_biotechacq.htm CONSENT OF MICHAEL SHLEIFER TO BE NAMED AS A DIRECTOR

Exhibit 99.9

 

Consent to be Named as a Director

 

In connection with the filing by Biotech Acquisition Company of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of Biotech Acquisition Company following the consummation of the business combination, which will be renamed Blade Biotherapeutics, Inc. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.

 

Dated: April 20, 2022

 

  By: /s/ Michael Schleifer
    Michael Schleifer